Norway · Delayed Price · Currency is NOK Thor Medical ASA Earnings Call Transcripts
Fiscal Year 2026
-
AlphaOne is now operational, enabling first commercial deliveries and strong revenue visibility through NOK 850 million in sales agreements. H1 2026 saw NOK 900,000 in revenue and a negative EBITDA, but ramp-up is on track with EBITDA breakeven expected in 2027.
Fiscal Year 2025
-
AlphaOne remains on track for completion and production ramp-up, supported by a NOK 850 million order backlog and strong market demand for alpha-emitting isotopes. The company is fully funded to reach cash-positive operations by 2027, with significant revenue potential and a growing customer base.
-
First commercial sales and major strategic agreements validate technology and market position. AlphaOne plant is fully funded, on schedule for 2026, and capacity was expanded by 40% after a successful capital raise. Revenue potential is strong, with a NOK 770 million order backlog and ambitious growth plans.
Fiscal Year 2024
-
Transitioned from pilot to commercial phase with Alpha One fully funded and construction set to begin. Secured key sales agreements, validated technology, and positioned to meet surging demand in a rapidly growing radiopharmaceuticals market.
-
The company aims to become a leading supplier of lead-212 for targeted alpha therapies, leveraging a proprietary, scalable, and environmentally friendly production process. With a $1 billion revenue ambition and global expansion plans, it is positioned to address the growing demand for radiopharmaceuticals and support the shift toward alpha-based cancer treatments.
-
Leadership transition and strategic focus on radiopharmaceuticals position the company for growth, with a pilot plant nearing completion and Fast Track scale-up planned. Financials show a loss but sufficient funding for current operations, while market conditions remain highly favorable.